| Psychedelic trials 2021 |
| MAPS |
| Post-traumatic stress disorder (PTSD) |
| MDMA |
| Phase III |
|
| Compass Pathways |
| Treatment-resistant depression (TRD) |
| COMP360 |
| Phase II |
|
| Usona Institute |
| Major depressive disorder (MDD) |
| Psilocybin |
| Phase II |
|
| MAPS |
| Eating disorders (anorexia nervosa and binge-eating disorder) |
| MDMA |
| II |
|
| MAPS |
| Anxiety associated with a life-threatening illness |
| MDMA |
| II |
|
| MAPS |
| Social anxiety in autistic adults |
| MDMA |
| II |
|
| MindMed |
| Anxiety |
| LSD |
| II |
|
| MindMed |
| Cluster headaches |
| LSD |
| II |
|
| Seelos Therapeutics |
| Acute suicidal ideation and behaviour (ASIB) in major depressive disorder |
| SLS-002 |
| II |
|
| Awakn Life Sciences |
| Alcohol use disorder |
| MDMA |
| II |
|
| B.More |
| Alcohol use disorder |
| Psilocybin |
| II |
|
| Braxia Scientific |
| Treatment-resistant depression |
| Psilocybin |
| II |
|
| Tryp Therapeutics |
| Overeating disorders |
| TRP-8802 |
| II |
|
| Compass Pathways |
| Post-traumatic stress disorder (PTSD) |
| COMP360 |
| II |
|
| Cybin |
| Major depressive disorder |
| CYB001 |
| II |
|
| DemeRx Logo |
| Opioid use disorder |
| DMX-NB1 |
| II |
|
| Eleusis Logo |
| Major depressive disorder (adjunctive treatment) |
| ELE-Ket+ |
| II |
|
| Incannex |
| Generalized anxiety disorder |
| Psilocybin |
| II |
|
| MAPS Logo |
| CBCT for PTSD |
| MDMA |
| II |
|
| MindMed |
| Attention deficit hyperactivity disorder (ADHD) |
| LSD |
| II |
|
| MindMed |
| Undisclosed severe pain indication |
| LSD |
| II |
|
| Mydecine Innovations |
| Post-traumatic stress disorder (PTSD) |
| Psilocybin |
| II |
|
| Perception Neuroscience |
| Treatment-resistant depression (TRD) |
| PCN-101 |
| II |
|
| Pharmather |
| Levodopa-induced dyskinesia in patients with Parkinson’s disease |
| Ketamine |
| II |
|
| GH Research |
| Treatment-resistant depression (TRD) |
| GH001 |
| I / II |
| Small Pharma |
| Major depressive disorder (MDD) |
| SPL026 |
| I / II |
|
| DemeRx |
| Opioid use disorder |
| DMX-1002 |
| I / II |
|
| Beckley Psytech |
| Undisclosed |
| 5-MeO-DMT |
| I |
|
| Eleusis |
| Alzheimer’s Disease |
| ELE-LSD |
| I |
|
| MindMed |
| Opioid use disorder |
| 18-MC |
| I |
|
| MindMed |
| Undisclosed |
| DMT |
| I |
|
| MindMed |
| Undisclosed |
| MDMA+LSD |
| I |
|
| MindMed |
| Undisclosed |
| Mescaline |
| I |
|
| MindMed |
| Ketanserin |
| I |
|
| Algernon Pharmaceuticals |
| Ischemic stroke and post-stroke rehabilitation |
| AP-188 |
| I |
|
| Beckley Psytech Logo |
| Short-lasting unilaterial neuralgiform headache attacks (SUNHA) |
| Psilocybin |
| I |
|
| Ceruvia Lifesciences |
| Cluster headache |
| NYPRG-101 |
| I |
|
| Ceruvia Lifesciences |
| Migraine |
| NYPRG-101 |
| I |
|
| Ceruvia Lifesciences |
| Migraine |
| SYNP-101 |
| I |
|
| Ceruvia Lifesciences |
| Cluster headache |
| SYNP-101 |
| I |
|
| Ceruvia Lifesciences |
| Obsessive compulsive disorder |
| SYNP-101 |
| I |
|
| Diamond Therapeutics |
| Anxiety |
| Psilocybin |
| I |
|
| Entheon Biomedical Logo |
| (Unspecified) Substance use disorder |
| DMT |
| I |
|
| Filament Health invite |
| Undisclosed |
| PEX010 |
| II |
|
| Health invite |
| Undisclosed |
| PEX020… |
| I |
|
| Filament Health invite |
| Undisclosed |
| PEX030… |
| I |
|
| Journey Colab |
| Alcohol use disorder |
| JOUR-001 |
| I |
|
| MindMed |
| Social anxiety associated with Autism Spectrum Disorder |
| R-MDMA |
| I |
|
| Numinus logo |
| Undisclosed |
| PSYBINA |
| I |
|
| Sacred Medicines |
| Undisclosed |
Ψ From Molecule to Mind — and beyond ∞
